Previous clinical studies have found epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) represented by gefitinib can greatly improve the progression‐free survival (PFS) of advanced EGFR‐mutant NSCLC, making EGFR‐TKI its standard first choice.3, 4, 5, 6. Here, EGFR is linked to non-small cell lung carcinoma.